Nycomed Amersham may be planning to bring a CT contrast injector system to market. Food and Drug Administration records indicate that the agency on Feb. 19 granted 510(k) clearance to the Anglo-Norwegian company for a device called Premica, listed as a
Nycomed Amersham may be planning to bring a CT contrast injector system to market. Food and Drug Administration records indicate that the agency on Feb. 19 granted 510(k) clearance to the Anglo-Norwegian company for a device called Premica, listed as a CT contrast media delivery system.
If Nycomed Amersham does bring such a product to market, it would compete with contrast injectors from companies owned by two of Nycomed's competitors in the contrast business, Schering and Mallinckrodt. Schering owns Medrad of Indianola, PA, while Mallinckrodt owns St. Louis-based Liebel-Flarsheim. Nycomed does not currently market a contrast delivery system.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.